Balancing Risks and Benefits: Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis

Jan P Kleinjan*, Justin Blom, André P van Beek, Hjalmar R Bouma, Peter R van Dijk

*Corresponding author voor dit werk

OnderzoeksoutputAcademicpeer review

40 Downloads (Pure)

Samenvatting

Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are a new class of drugs that have been proven beneficial in the management of diabetes, chronic kidney disease, and heart failure and in the mitigation of cardiovascular risk. The benefits of SGLT2i therapy have led to the rapid adoption of these drugs in clinical guidelines. Since the introduction of these drugs, concerns have arisen, as diabetic ketoacidosis (DKA) unexpectedly occurred in patients treated with SGLT2i. DKA is an infrequent but serious complication of SGLT2i therapy, and is potentially preventable. The risk factors for the development of SGLT2i-associated DKA are inappropriate dose reductions of insulin, the dietary restriction of carbohydrates, and factors that may increase insulin demand such as excessive alcohol intake and major surgery. Moreover, the risk of SGLT2i-associated DKA is higher in persons with type 1 diabetes. It is crucial that both patients and healthcare providers are aware of the risks of SGLT2i-associated DKA. In an effort to encourage safe prescribing of this effective class of drugs, we present two cases that illustrate the risks of SGLT2i therapy with regard to the development of DKA.

Originele taal-2English
Artikelnummer162
Aantal pagina's7
TijdschriftMetabolites
Volume14
Nummer van het tijdschrift3
DOI's
StatusPublished - 13-mrt.-2024

Vingerafdruk

Duik in de onderzoeksthema's van 'Balancing Risks and Benefits: Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis'. Samen vormen ze een unieke vingerafdruk.

Citeer dit